Floatz logo

Palonosetron

Gastrointestinal Carcinoid Tumor

Alliance for Clinical Trials in OncologySmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Gastrointestinal Carcinoid Tumor cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Mayo Clinic
Phase 2/3BB
Irinotecan
National Cancer Institute (NCI)
Phase 3BB
Oxodotreotide
Vanderbilt-Ingram Cancer Center
Phase 4BB
Octreotide Pamoate
National Cancer Institute (NCI)
Phase 3BB
Eloxatin
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2/3BB

View all 44 →

Same molecule, other indications

Palonosetron is also rated in:

chemotherapy-induced toxicityDormant
A
Indicative ·
82 / 100
View asset →
Breast Cancer Patients Treated With T-DXdDormant
BBB
Indicative ·
74 / 100
View asset →
Nausea and VomitingDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →